Institute of Hematology & Blood Diseases Hospital, China: all 402 studies
Page 1 of 5. Open to participants first (296), then studies with results posted, then the rest; newest registration first within each.
- Nutritional Intervention for Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07850375Not applicable
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingNCT07840976Phase 2
- Human Albumin Combined With Plasma Exchange for Frailty InterventionNot yet recruitingNCT07836127Not applicable
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingNCT07831395Phase 2
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07830485Phase 2
- Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AMLNot yet recruitingNCT07828535Phase 1
- F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple MyelomaNot yet recruitingNCT07828522Phase 2
- Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07816341Phase 1
- HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary DiseaseNot yet recruitingNCT07811986Phase 2
- A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia ANot yet recruitingNCT07789587Not applicable
- Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaNot yet recruitingNCT07789522Phase 2
- A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia ANot yet recruitingNCT07788469Not applicable
- Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune ThrombocytopeniaRecruitingNCT07788456Phase 4
- A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesEnrolling by invitationNCT07784309Phase 1
- Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Associated With Hereditary Homocysteine Remethylation DisordersNot yet recruitingNCT07757685Not applicable
- Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.Not yet recruitingNCT07757672Phase 1/2
- A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid LeukemiaNot yet recruitingNCT07754799Phase 2
- Plasma ctDNA Monitoring in Pediatric Acute LeukemiaNot yet recruitingNCT07751588
- BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)Not yet recruitingNCT07751471Phase 2
- A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07726160Phase 1
- SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)Not yet recruitingNCT07725705Phase 1/2
- A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALLNot yet recruitingNCT07723911Phase 3
- Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaRecruitingNCT07714512Phase 1/2
- A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte LeukemiaNot yet recruitingNCT07692529Phase 1
- META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07689604Early Phase 1
- Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITPNot yet recruitingNCT07687134Phase 2
- Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic StratificationNot yet recruitingNCT07687004Phase 1/2
- Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of RelapseNot yet recruitingNCT07686965Phase 3
- A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/LymphomaNot yet recruitingNCT07678307Phase 1/2
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingNCT07652905Phase 2
- CM336-SOC for Dynamically High-Risk Multiple Myeloma StudyNot yet recruitingNCT07648459Phase 2
- Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionNot yet recruitingNCT07644481Not applicable
- Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella TrialNot yet recruitingNCT07643103Phase 2
- daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTNot yet recruitingNCT07588945Phase 3
- CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal ImpairmentRecruitingNCT07585760Phase 2
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingNCT07585747Phase 2
- IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingNCT07585071Phase 1
- Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRSRecruitingNCT07578675
- Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular LymphomaRecruitingNCT07555470Phase 2
- Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AMLNot yet recruitingNCT07539818Phase 3
- Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell LymphomaNot yet recruitingNCT07539688Phase 1
- Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Enrolling by invitationNCT07539662Not applicable
- Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic TumorsNot yet recruitingNCT07539610Phase 1
- A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.Not yet recruitingNCT07539233Early Phase 1
- Establishment of Biomarker Panel For Forecasting Chronic Graft-Versus-Host Disease (cGVHD) After Allo-HSCTNot yet recruitingNCT07539220Not applicable
- Study on the Pharmacokinetic Characteristics of Liposomal Amphotericin B in Patients With Invasive Fungal Infections Undergoing Plasma Exchange TherapyNot yet recruitingNCT07532850
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaRecruitingNCT07495631Not applicable
- Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell MalignanciesNot yet recruitingNCT07493174Phase 1
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLRecruitingNCT07493161Not applicable
- Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AMLRecruitingNCT07490288Not applicable
- Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT07490275Phase 1
- A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological DiseasesNot yet recruitingNCT07476885
- Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).Not yet recruitingNCT07476872Phase 1/2
- rhTPO Dose Escalation vs Eltrombopag Switch in ITPNot yet recruitingNCT07476846Not applicable
- Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALLNot yet recruitingNCT07476027Early Phase 1
- Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07476014Early Phase 1
- Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic AnemiaRecruitingNCT07471516Phase 1/2
- Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary MyelofibrosisNot yet recruitingNCT07471503Phase 2
- Adverse Effects of ATG/ALG Therapy in Aplastic AnemiaRecruitingNCT07461116
- The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary InfiltratingNot yet recruitingNCT07456189Not applicable
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALLRecruitingNCT07454226Not applicable
- The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCTNot yet recruitingNCT07450313Phase 2
- Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell LymphomaNot yet recruitingNCT07447726Phase 1/2
- Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis DurationNot yet recruitingNCT07443501
- Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALLNot yet recruitingNCT07443488Phase 2
- Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingNCT07441993Phase 2
- A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07441980Phase 1
- The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood TransplantationNot yet recruitingNCT07441967Phase 2
- Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent LymphomaNot yet recruitingNCT07441954Phase 1/2
- Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell DiseaseNot yet recruitingNCT07436767Not applicable
- MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple MyelomaRecruitingNCT07409454Phase 2
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AMLNot yet recruitingNCT07407140Phase 3
- BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMMNot yet recruitingNCT07407010Phase 1
- JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALLNot yet recruitingNCT07406178Early Phase 1
- PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）RecruitingNCT07406139Phase 4
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）Not yet recruitingNCT07399444Early Phase 1
- A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched TransplantationNot yet recruitingNCT07381114Phase 1/2
- A Cohort Study on the Association Between the ANS Function and Acute GvHDRecruitingNCT07374874
- Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT07362238Phase 2
- Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)RecruitingNCT07362199Phase 2
- A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins ProphylaxisRecruitingNCT07357038
- HID-HSCT Versus IST as First-line Treatment for SAANot yet recruitingNCT07338422Not applicable
- Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant PatientsNot yet recruitingNCT07324291
- IASO206 in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07322159Early Phase 1
- CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesRecruitingNCT07315087Phase 1
- Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AMLRecruitingNCT07304232Phase 2
- Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular LymphomaRecruitingNCT07299149Phase 2
- Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood TransplantationRecruitingNCT07297576Not applicable
- Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)RecruitingNCT07297563Phase 2
- Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaNot yet recruitingNCT07297550Phase 1/2
- The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaNot yet recruitingNCT07287228Phase 1/2
- Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune ThrombocytopeniaNot yet recruitingNCT07278908Phase 2/3
- Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALLRecruitingNCT07278882Not applicable
- National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) PatientsNot yet recruitingNCT07268898
- Zuberitamab for EBV Infection Post-Allo-HSCTNot yet recruitingNCT07261215Phase 2
- Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaRecruitingNCT07261163Phase 2
- Modified Conditioning Regimen for CML-BPNot yet recruitingNCT07259161Phase 2
- A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaNot yet recruitingNCT07259122Phase 2
- Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell LymphomaRecruitingNCT07259070Phase 1/2
- Cohort of Cord Blood BankEnrolling by invitationNCT07249099
← Institute of Hematology & Blood Diseases Hospital, China overview and focus areas